Tuesday, June 7, 2022 Daily Archives

Time-To-Market Record: Major EPCM Project in Just 24 Months

by

Boehringer Ingelheim and ZETA have had a long-standing, successful partnership. In 2019, the global pharmaceutical company approached ZETA with a significant challenge. The goal was to implement a major EPCM project at the Boehringer Ingelheim RCV site in Vienna, Austria, in just 24 months. ZETA accepted the challenge and successfully managed the entire project – called G3Leopold – as a one-stop-shop for the customer. Everything was included: from the engineering of the entire plant, the process area, the architecture, and…

June 7, 2022

Gilead: CAR-T still in infancy but the future is both auto and allo

by

Investment and innovation will continue to pour into autologous CAR-T therapies even as allogeneic products begin to impact the market, according to Gilead Sciences. Gilead Sciences is a pioneer in the cell therapy space, acquiring Kite Pharma in 2017 months ahead of the FDA approving Yescarta (axicabtagene ciloleucel), the second CAR-T therapy to achieve commercial success. Gilead won approval for a second autologous CAR-T, Tecartus (brexucabtagene autoleucel), in July 2020. Talking at the Bernstein Annual Strategic Decisions Conference last week,…

June 7, 2022

CordenPharma pushing into RNA space through lipid expansion

by

CordenPharma has invested over $10 million into expanding Lipid Nanoparticle (LNP) formulation, development, and production at its site in Italy to support the burgeoning xRNA market. The investment at the sterile injectable facility in Caponago, Italy aims to support customers developing ‘xRNA’ based vaccine and therapeutics – including mRNA, siRNA, saRNA, microRNA – through LNP formulation and production. “We believe that the xRNA market is going to be a significant potential market moving forward,” a spokesperson from CordenPharma told Bioprocess…

June 7, 2022